Research graph
References from Accumulating Evidence Supports NECTIN4 as a Predictive Biomarker for Enfortumab Vedotin: The Compartment Still Matters. Local targets link to admitted publications; unresolved targets remain external evidence.
Enfortumab vedotin and pembrolizumab in cisplatin-eligible bladder cancer
10.1056/nejmoa2601486 · 2026 · External reference
1966MO EV-302: exploratory analysis of nectin-4 expression and response to 1L enfortumab vedotin (EV) + pembrolizumab (P) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC)
10.1016/j.annonc.2024.08.2051 · 2024 · External reference
Unresolved reference
External reference
Associations of TACSTD2/TROP2 and NECTIN‐4/NECTIN‐4 with molecular subtypes, PD‐L1 expression, and FGFR3 mutational status in two advanced urothelial bladder cancer cohorts
10.1111/his.15130 · 2024 · External reference
NECTIN4 amplification is frequent in solid tumors and predicts enfortumab vedotin response in metastatic urothelial cancer
10.1200/jco.23.01983 · 2024 · External reference
Membranous NECTIN-4 expression frequently decreases during metastatic spread of urothelial carcinoma and is associated with enfortumab vedotin resistance
10.1158/1078-0432.ccr-22-1764 · 2023 · External reference
Unresolved reference
External reference
Membranous nectin-4 expression to predict enfortumab vedotin response in metastatic urothelial carcinoma
10.1200/jco.2026.44.7_suppl.854 · 2026 · External reference
Membranous and cytoplasmic nectin4 expression and outcomes with enfortumab vedotin plus pembrolizumab in metastatic urothelial carcinoma
10.1200/jco.2026.44.7_suppl.801 · 2026 · External reference
Nectin-4 positivity in genitourinary malignancies: a systematic review
2024 · External reference
Integrating NECTIN4 Amplification with Membranous NECTIN4 Expression to Develop a Scoring System for Predicting Enfortumab Vedotin Response in Urothelial Carcinoma
10.1158/1078-0432.ccr-26-0093 · 2026 · External reference
